The central feature of the immune system is the specificity of antigen-binding proteins for the ligand that induced their synthesis. It is this specificity that has intrigued medical scientists for the last 100 years and has led to repeated attempts to use this feature to combat disease. One of the earliest, successful uses of immune specificity involved the production of specific anti-toxins to combat a variety of ills from bacterial infections to snake bites [1]. In addition, advantage was taken of the fact that by providing appropriate antigens in the proper form (eg. viruses, bacteria), specific immune responses could be elicited [2]. Thus, over the last 80 years or so the primary focus of the therapeutic use of antigen-specific proteins has been the antibody molecule [3]. With the development of monoclonal antibody methodology, there has developed a renewed interest in the use of specific single antibodies as therapeutic agents; “magic bullets” as they are often termed [4]. In addition, the capacity to produce monospecific reagents is providing invaluable tools to probe the structure and function of other proteins; to use in the specific detection of cellular or tissue specific antigens and for purifying and identifying a wide variety of normal body components (eg. peptides, lipids, etc.) and/or ingested drugs [5]. In the early 1970s several groups of investigators reported that, in addition to antibodies, there exist other antigen-binding moieties that appear to function primarily as immune regulators.KeywordsDrug ResearchHelper FactorTissue Specific AntigenImmune Response ModelModulate Factor ActivityThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Read full abstract